ABBV Q3 2026 guidance cut by $0.11 per share on IPR&D milestones

AbbVie incurred $216 million in acquired IPR&D and milestone expenses in Q3 2026, reducing both GAAP and adjusted EPS by $0.11 per share. The company lowered full-year adjusted EPS guidance to $13.76–$13.96 from the prior range that excluded post-Q2 IPR&D charges, representing a material but previously disclosed category of uncertain costs.

AbbVie had to pay $216 million in upfront costs for drug development deals and licensing in Q3, which cuts their expected profit per share by 11 cents for the year. This was not a surprise cut—they had said such costs might happen.